---
title: "Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292507452.md"
description: "Jefferies maintained a Buy rating on Denali Therapeutics (DNLI) with a $40 price target. Meanwhile, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies. The current analyst consensus for Denali Therapeutics remains a Strong Buy, with an average price target of $34.11."
datetime: "2026-07-13T15:15:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292507452.md)
  - [en](https://longbridge.com/en/news/292507452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292507452.md)
---

# Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $34.11.

### Related Stocks

- [DNLI.US](https://longbridge.com/en/quote/DNLI.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Denali Therapeutics sells priority review voucher for $195 million gross proceeds](https://longbridge.com/en/news/294046240.md)
- [Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI](https://longbridge.com/en/news/294581286.md)
- [Viking Therapeutics (VKTX) Receives a Buy from Jefferies](https://longbridge.com/en/news/294386403.md)
- [Denali wins FDA accelerated approval for Hunter syndrome brain-penetrant enzyme therapy AVLAYAH](https://longbridge.com/en/news/292237326.md)
- [Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return](https://longbridge.com/en/news/293133442.md)